NDA 202107 · Corcept Therap
Korlym
Mifepristone · Oral · Progestin Antagonist
OrphanLast checked: Nov 20, 2026Latest source record: Nov 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Feb 17, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
184
37 Phase 3, 8 recruiting
FAERS reports
4,775
2,955 serious, 352 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with KORLYM and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential. WARNING: TERMINATION OF PREGNANCY See full prescribing information for complete boxed warning. Mifepristone has potent antiprogestational effects and will result in the termination of...
What it is approved for
From the label in effect Sep 25, 2025.
KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery ( 1 ). Important Limitations of Use: Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.
Mechanism: Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 17, 2012 Original approval · Type 5 - New Formulation or New Manufacturer OrphanReviewSummary ReviewLetter
1 products under this application
- KORLYM · MIFEPRISTONE 300MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mifepristone" as an intervention, any sponsor and status, largest first.
- The Misoprostol-Only Regimen Evidence StudyPivotal-lookingNot yet recruiting
Ibis Reproductive HealthAcademic, hospital or other
NCT07174856 · 1,900 participants (planned) · Start Oct 10, 2025 · Primary completion Jan 2027
Drug: Misoprostol-only medication abortion regimen; Combined regimen · For: Abortion, Medical
Sites: Salt Lake City, Utah
Gynuity Health ProjectsAcademic, hospital or other
NCT01798017 · 1,738 participants · Start Nov 2012 · Primary completion Jun 2015
Drug: Mifepristone and misoprostol · For: Menstrual Regulation
Sites: Aminbazar, Bangladesh; Savar Upazila, Bangladesh; Tetuljhora, Bangladesh · 8 sites in all
- Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days GestationPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT00286208 · 1,443 participants · Start Aug 2005 · Primary completion Jan 2008
Drug: Mifepristone, misoprostol · For: Induced Abortion
Sites: Chisinau, Moldova; Aryanah, Tunisia; Tunis, Tunisia · 9 sites in all
Gynuity Health ProjectsAcademic, hospital or other
NCT00997347 · 1,400 participants · Start Jul 2009 · Primary completion Feb 2012
Drug: Mifepristone and misoprostol · For: Medical Abortion
Sites: West Palm Beach, Florida; Chicago, Illinois; Boston, Massachusetts · 12 sites in all
- Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal MisoprostolCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT00386282 · 1,250 participants · Start Sep 2006 · Primary completion Mar 2011
Drug: mifepristone-misoprostol treatment · For: Abortion, First Trimester
Sites: Yerevan, Armenia; Baku, Azerbaijan; Mexico City, Mexico · 11 sites in all
- Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days GestationPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT00482209 · 1,220 participants (planned) · Start May 2007 · Primary completion Oct 2009
Drug: Mifepristone, misoprostol; mifepristone, misoprostol · For: Induced Abortion
Sites: Tbilisi, Georgia; Ho Chi Minh City, Vietnam · 4 sites in all
- A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMPPivotal-lookingCompleted
Gynuity Health ProjectsAcademic, hospital or other
NCT00386867 · 1,200 participants (planned) · Start Oct 2006
Drug: 800 mcg misoprostol via oral or buccal administration · For: Abortion, Induced
Sites: Chicago, Illinois; Boston, Massachusetts; New York, New York · 8 sites in all
- Mifepristone at Same Time Multicenter StudyPivotal-lookingCompleted
University of PittsburghAcademic, hospital or other
NCT00269568 · 1,128 participants · Start Jun 2004 · Primary completion Apr 2006
Drug: mifepristone and misoprostol · For: Abortion Seekers
Sites: Los Angeles, California; Chicago, Illinois; Portland, Oregon · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea805
- fatigue700
- blood potassium decreased457
- vomiting442
- dizziness408
- headache392
- haemorrhage361
- blood pressure increased350
- abortion incomplete335
- blood glucose increased321
- asthenia286
- blood glucose decreased285
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 51 |
| 2005 | 5 |
| 2006 | 18 |
| 2007 | 24 |
| 2008 | 36 |
| 2009 | 3 |
| 2010 | 72 |
| 2011 | 1 |
| 2012 | 95 |
| 2013 | 241 |
| 2014 | 406 |
| 2015 | 332 |
| 2016 | 201 |
| 2017 | 344 |
| 2018 | 409 |
| 2019 | 298 |
| 2020 | 379 |
| 2021 | 297 |
| 2022 | 351 |
| 2023 | 274 |
| 2024 | 245 |
| 2025 | 364 |
| 2026 | 329 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Korlym (Mifepristone)
2024 spending
$342M
Beneficiaries
1,700
10,079 claims
Per beneficiary
$201,039
$691.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $153,690,299 |
| 2021 | $165,795,595 |
| 2022 | $187,312,598 |
| 2023 | $228,814,734 |
| 2024 | $341,766,725 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Methods for managing miscarriage: a network meta-analysis.
Ghosh J, Papadopoulou A, Devall AJ, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- [Medical induced abortion].
Bettahar K, Pinton A, Boisramé T, et al. · J Gynecol Obstet Biol Reprod (Paris) 2016 · Systematic Review
- Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.
DeFronzo RA, Fonseca V, Aroda VR, et al. · Diabetes Care 2025 · Randomized Controlled Trial, Multicenter Study
- Interventions for emergency contraception.
Shen J, Che Y, Showell E, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interventions for emergency contraception.
Cheng L, Gülmezoglu AM, Piaggio G, et al. · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Mifepristone for uterine fibroids.
Tristan M, Orozco LJ, Steed A, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Corcept Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.